Insider · CIK 0001789335
Mitchell Chan
cfoofficerdirector
Files at AVTX (Avalo Therapeutics, Inc.), RGNX (REGENXBIO Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | RGNX REGENXBIO Inc. | FTax withholding Common Stock | -4,902 | $9.32 | $46k | 122,815 | 39 d ago |
| Sep 1, 2025 | RGNX REGENXBIO Inc. | FTax withholding Common Stock | -4,901 | $8.93 | $44k | 53,968 | Sep 3, 2025 |
| Jun 17, 2025 | AVTX Avalo Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +20,100 | $0.00 | $0 | 20,100 | Jun 18, 2025 |
| Mar 28, 2025 | AVTX Avalo Therapeutics, Inc. | MOption exercise Common Stock | +3,167 | - | - | 3,167 | Apr 1, 2025 |
| Mar 28, 2025 | AVTX Avalo Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -3,167 | $0.00 | $0 | 6,333 | Apr 1, 2025 |
| Jan 2, 2025 | RGNX REGENXBIO Inc. | AGrant or award Stock Options (Right to buy)derivative | +62,547 | $0.00 | $0 | 62,547 | Jan 6, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.